TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Scientific Advisory Board to Drive RNA Oncology Advancements

Reuters
28 May
TransCode <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Appoints Dr. Phillip D. Zamore to Scientific Advisory Board to Drive RNA Oncology Advancements

TransCode Therapeutics, Inc. has announced the appointment of Dr. Phillip D. Zamore to its Scientific Advisory Board. Dr. Zamore, a co-founder of Alnylam Pharmaceuticals and a prominent figure in RNA interference research, will contribute his expertise to advance TransCode's mission of developing RNA-targeted cancer therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE97347) on May 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10